Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-03-29 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
董事会可持续发展委员会工作细则
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 董事会可持续发展委员会工作细则', which translates to 'Yunnan Watson Biotechnology Co., Ltd. Board of Directors Sustainable Development Committee Working Rules'. The content details the structure, responsibilities, decision-making procedures, and rules of the Board's Sustainable Development Committee, focusing on ESG (Environmental, Social, and Governance) matters. It is a governance-related document outlining internal rules and committee operations rather than a report of financial results, voting outcomes, or announcements. It does not contain financial data, voting results, or legal proceedings. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-03-29 Chinese
2023年度独立董事述职报告（曾令冰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2023 of Yunnan Watson Biotechnology Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, communication with audit firms, and compliance with laws and regulations. The content focuses on the independent director's duties, opinions on governance, internal controls, and company operations during the year. It is not a full annual report, audit report, or financial statement, but rather a detailed report on the independent director's role and activities. This type of document aligns with Board/Management Information (MANG), as it relates to management and board-level disclosures about governance and director duties.
2024-03-29 Chinese
关联交易决策制度（2024年3月）
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 关联交易决策制度' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Related Party Transaction Decision System'. It details the company's internal policies and procedures regarding related party transactions, including definitions, reporting, decision-making authority, disclosure, and other governance aspects. There are no financial statements, audit opinions, earnings data, or regulatory filings of financial results. The document is a governance policy document outlining internal rules and procedures for related party transactions, which fits the definition of Governance Information (CGR). The document length is 5682 characters, which is sufficient for a full policy document rather than a brief announcement or notice. Therefore, the appropriate classification is Governance Information (CGR).
2024-03-29 Chinese
关于终止向不特定对象发行可转换公司债券事项并撤回申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the termination of a planned convertible bond issuance and the withdrawal of the related application documents. It details board and supervisory committee meetings, decisions made, and the rationale behind the termination. There are no financial statements or detailed financial data presented, nor is this a transcript, report, or presentation. The document is a formal announcement about a capital market activity (termination of a financing plan and withdrawal of application). This fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the announcement of a financing decision. Therefore, the correct classification is CAP with high confidence.
2024-03-29 Chinese
华创证券有限责任公司关于公司2023年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from 华创证券有限责任公司 (Huachuang Securities Co., Ltd.) regarding the 2023 annual special audit on the deposit and use of raised funds by 云南沃森生物技术股份有限公司 (Yunnan Watson Biotechnology Co., Ltd.). It references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, and includes extensive financial data on the amount of funds raised, their usage, management, and compliance with relevant laws. The document contains detailed tables and explanations about the raised funds, their investment projects, changes in project implementation, and audit opinions. This is a specialized audit report focusing on the raised funds' management and usage, not a full annual report or earnings release. It is not a brief announcement or a certification letter but a substantive financial and compliance report. Therefore, it fits the definition of an Audit Report / Information (AR). FY 2023
2024-03-29 Chinese
2023年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度董事会工作报告" (2023 Annual Board of Directors Work Report) of Yunnan Watson Biotechnology Co., Ltd. It contains a detailed review of the company's operations, product sales, production, R&D, international cooperation, internal control, and governance activities for the year 2023. It also includes a summary of board meetings, independent directors' duties, committee activities, and shareholder meetings. The content is comprehensive and focuses on the board's work and governance over the year, rather than being a full annual financial report or an earnings release. It is not a simple announcement or a proxy statement but a detailed report on board activities and governance. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements and reports related to the company's board of directors and senior management activities.
2024-03-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.